Investor Relations

Diagonal Bio is a Swedish biotech company that has developed a ground breaking universal technology platform for the quick and accurate detection of genetic markers in genetic material (DNA and RNA).

Background

Diagonal Bio AB is a Swedish medical technology company founded in 2020 with the vision of limiting the spread of infectious diseases by creating a user-friendly, cost-effective diagnostic platform with high accuracy. Based on its patented technology, Diagonal Bio plans to develops a diagnostic systems, PANVIRAL™, that have the potential to fulfill the vision and thereby facilitate the challenge of rapidly and accurately identifying genetic markers for infectious diseases.

Diagonal Bio’s patented technology can also be used for other purposes outside the market segment for in-vitro diagnostics, for example as a general laboratory equipment quick, accurate and cost-effective identification of genetic markers (LAMPlify®).

Diagonal Bio’s patented technology

Diagonal Bio’s patented technology offers the same accuracy as today’s leading diagnostic method, PCR, but is not dependent on complicated logistics or large central laboratories and is therefore significantly faster and more cost-effective. With the help of the Company’s technology, today’s and future infectious diseases can be diagnosed within 10–15 minutes of sampling, in connection with a visit to, for example, a primary care unit.

Diagonal Bio’s platform technology can also be used for other purposes outside the market segment for in-vitro diagnostics, for example as a general laboratory equipment quick, accurate and cost-effective identification of genetic markers (LAMPlify®). This, too, with the same high accuracy as today’s PCR-based techniques, but in a significantly faster, simpler and more cost-effective.

[1] Agricultural and Environmental Diagnostics Market Size (2028) (businessresearchinsights.com)

[2] Food Safety Testing Market Size Will Attain 35.6 Billion by (globenewswire.com)

[3] Infectious Disease Diagnostic Market Statistics | Forecast – 2030 (alliedmarketresearch.com)

Press Releases

Subscribe

Stall Courant and Diagonal Bio agree to a pilot test of LAMPlify®

Regulatory

Diagonal Bio AB (publ) (“Diagonal Bio” or “the Company”) and Stall Courant, owned by Unibet founder Anders Ström and run by trotting trainer Sabine Kagebrant, have signed an agreement regarding a three-month pilot test of the LAMPlify® platform.

Read more

Diagonal Bio has been approved for delisting from Nasdaq First North Growth Market

Regulatory

Diagonal Bio AB (publ) (“Diagonal Bio” or “the Company”) today announces that Nasdaq has approved Diagonal Bio’s application for delisting from Nasdaq First North Growth Market (“First North”). The last day of trading on First North is 18 March 2025 and the Company will instead be listed on NGM Nordic SME (“NGM”) with a planned first day of trading on 19 March 2025, provided that no new information emerges that affects the listing.

Read more

Diagonal Bio has received conditional approval for listing on NGM Nordic SME

Regulatory

Diagonal Bio AB (publ) (“Diagonal Bio” or “the Company”) has received conditional approval for listing on NGM Nordic SME (“NGM”). The first day of trading is planned for 19 March 2025. This means that Diagonal Bio changes marketplace from Nasdaq First North Growth Market (“First North”).

Read more

Diagonal Bio applies for change of marketplace to NGM Nordic SME

Regulatory

Diagonal Bio AB (publ) (“Diagonal Bio” or “the Company”) today announces that the Company – in order to be able to reallocate costs – has decided to apply for listing on NGM Nordic SME (“NGM”). The decision is based on the evaluation that the move from Nasdaq First North Growth Market to NGM will result in lower costs and thus possibilities for Diagonal Bio to allocate more of the available capital to marketing and sales.

Read more

Diagonal Bio AB’s announces last day of trading in BTU and first day of trading in warrants of series TO 2

Regulatory

Diagonal Bio AB’s (“Diagonal Bio” or the “Company”) rights issue of units, with a subscription period ending on 6 February 2025, has now been registered at the Swedish Companies Registration Office together with the directed issue of units which was conducted at the same time. The Company hereby announces that the last day of trading in BTU (paid subscribed unit) is 24 February 2025, and the cut-off date is 26 February 2025. The first day of trading in warrants of series TO 2 is 28 February 2025.

Read more

News

Revisor

Mazars, Revision

Scheelevägen 17
223 63 Lund
Sweden

Articles of association

Contact us

Karin Wehlin
CEO, Diagonal Bio
Medicon Village, Lund
Phone: +46 (0)70 305 24 88
kw@diagonalbio.com

Certified advisor

Svensk Kapitalmarknadsgranskning AB
www.skmg.se

Phone: +46 (0)8 913 008
E-mail: ca@skmg.se

Issuer

Nordic Issuing AB
Stortorget 3
211 22 Malmö